Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Seminars in Cancer Biology|September 10, 2003
Immunotherapy with anti-CD20 compoundsChristoph von Schilling
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 9, 2006
Acupuncture and acupressure for the prevention of chemotherapy-induced nausea--a randomised cross-over pilot studyDieter Melchart, Angela Ihbe-Heffinger, Birgit Leps, et al.
Virchows Archiv : an International Journal of Pathology|October 19, 2005
Immunohistochemistry in bone marrow pathology: a useful adjunct for morphologic diagnosisMarcus Kremer, Leticia Quintanilla-Martínez, Jörg Nährig, et al.
Respiration; International Review of Thoracic Diseases|August 14, 2014
Response to chemotherapy, reexposure to crizotinib and treatment with a novel ALK inhibitor in a patient with acquired crizotinib resistanceKathrin Schrödl, Christoph von Schilling, Amanda Tufman, et al.
Leukemia & Lymphoma|July 8, 2008
Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: analysis of remission induction and stem cell mobilizationHelge Menzel, Andrea Müller, Christoph Von Schilling, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 22, 2005
Determination of individual S-values for 131I using segmented CT data and the EGS4 Monte Carlo codeIngo Wolf, Maria Zankl, Klemens Scheidhauer, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 13, 2011
Blood component use and associated costs after standard dose chemotherapy--a prospective analysis of routine hospital care in lymphoproliferative disorders and NSCLC in GermanyBernadette Paessens, Angela Ihbe-Heffinger, Christoph von Schilling, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 25, 2002
Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphomaKlemens Scheidhauer, Ingo Wolf, Hans-Joachim Baumgartl, et al.
The American Journal of Surgical Pathology|August 27, 2010
Peripheral T-cell lymphoma with progression to a clonally related, Epstein Barr virus+, cytotoxic aggressive T-cell lymphoma: evidence for secondary EBV infection of an established malignant T-cell cloneRupert Langer, Eva Geissinger, Thomas Rüdiger, et al.
Leukemia & Lymphoma|April 7, 2009
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation studyOliver Weigert, Eckhart Weidmann, Rudolf Mueck, et al.
Pageof 2